A pill to treat Covid developed by the US company Pfizer cuts the risk of hospitalisation or death by 89% in vulnerable adults, clinical trial results suggest. The drug – Paxlovid – is intended for use soon after symptoms develop in people at high risk of severe disease. It comes a day after the UK medicines regulator approved a similar treatment from Merck Sharp and Dohme (MSD). Pfizer says it stopped trials early as the initial results were so positive. The UK has already ordered 250,000 courses of the new Pfizer treatment, which has not yet been approved, along with another 480,000 courses of MSD’s molnupiravir pill. Health and Social Care Secretary Sajid Javid called the results “incredible”, and said the UK’s medicines regulator would now assess its safety and effectiveness. “If approved, this could be another significant weapon in our armoury to fight the virus alongside our vaccines and other treatments,” he said. The Pfizer drug, known as a protease inhibitor, is designed to block an enzyme the virus needs in order to multiply. When taken alongside a low dose of another antiviral pill called ritonavir, it stays in the body for longer.(BBC)…[+]